Amavu n'amavuko

Canagliflozin ni igitabo gishya, gikomeye, kandi cyatoranijwe cyane cya sodium glucose co-transport (SGLT) 2 inhibitor [1]. Byaragaragaye ko Canagliflozin ishobora kongera inkari glucose isohoka mu kugabanya impyiko ya glucose yimpyiko no kugabanya glucose yungurujwe yongeye kwinjizwa [2].

Canagliflozin yerekanwe kubuza gufata Na + -guhuza 14C-AMG muri CHO-hSGLT2, CHO-imbeba SGLT2 na CHO-imbeba SGLT2 ifite IC50 ifite agaciro ka 4.4, 3.7 na 2.0 nM, [1].

Bivugwa ko Canagliflozin igabanya urugero rw'amaraso glucose (BG) ikabije bitewe na db / db Imbeba na Zucker ibinure bya diyabete (ZDF). Byongeye kandi, canagliflozin yerekanye ko igabanya igipimo cy’imyanya y'ubuhumekero, n'uburemere bw'umubiri mu mbeba za DIO n'imbeba ZDF [1].

Canagliflozin irashobora gufatwa mu kanwa [1].

Reba:
[1] Liang Y1, Arakawa K, Ueta K, Matsushita Y, Kuriyama C Martin T, Du F, Liu Y, Xu J, Conway B, Conway J, Polidori D, Inzira K, Demarest K. Ingaruka za canagliflozin ku mpyiko kuri glucose, glycemia, nuburemere bwumubiri muburyo busanzwe bwinyamaswa na diyabete. PLOS Umwe. 2012; 7 (2): e30555
[2] Sarnoski-Brocavich S, Hilas O. Canagliflozin (Invokana), Umukozi wo mu kanwa wa Diyabete yo mu bwoko bwa 2. P T. 2013 Ugushyingo; 38 (11): 656-66

Ibicuruzwa byatanzwe

Bahia Abbas Moussa, Marianne Alphonse Mahrouse, n'abandi. . Spectrochimica Acta Igice A: Molecular na Biomolecular Spectroscopy Iraboneka kumurongo 20 Kamena 2018.

Imiterere yimiti